Enrichment in pathways like ErbB, insulin signaling, and focal adhesion aligns with CMap predictions, suggesting potential for repurposing these inhibitors in neurodegenerative diseases, fibrosis, and metabolic disorders. The gene discussed is EGFR; the disease is Other metabolic disease.